Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022)

Alkermes' (ALKS) quarterly Non-Current Deffered Revenue came in at $6.4 million in Q3 2022, down 50.25% year-on-year from $12.9 million in Q3 2021, and down 44.3% on a QoQ basis from $11.5 million in Q4 2021.

Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends

Alkermes (ALKS) has 12 years of Non-Current Deffered Revenue data on file, last reported at $6.4 million in Q3 2022.

  • On a quarterly basis, Non-Current Deffered Revenue fell 50.25% year-over-year to $6.4 million in Q3 2022; TTM through Sep 2022 was $6.4 million, a 50.25% decrease from a year earlier, with the FY2021 full-year figure at $11.5 million, down 29.92% from the prior year.
  • Non-Current Deffered Revenue for Q3 2022 stood at $6.4 million, down from $11.5 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for ALKS reached as high as $22.1 million in Q4 2019 and fell as low as $5.0 million in Q3 2018.
  • Historically, Non-Current Deffered Revenue has averaged $12.8 million across 5 years, with a median of $11.6 million in 2019.
  • Across the five-year window, Non-Current Deffered Revenue surged 131.69% in 2019 and sank 50.25% in 2022, its largest moves.
  • Year by year, Non-Current Deffered Revenue stood at $9.5 million in 2018, then jumped by 131.69% to $22.1 million in 2019, then declined by 25.7% to $16.4 million in 2020, then fell by 29.92% to $11.5 million in 2021, then tumbled by 44.3% to $6.4 million in 2022.
  • Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $6.4 million in Q3 2022, $11.5 million in Q4 2021, and $12.9 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2022 6.40 Mn
Dec 31, 2021 11.49 Mn
Sep 30, 2021 12.86 Mn
Jun 30, 2021 14.17 Mn
Mar 31, 2021 14.75 Mn
Dec 31, 2020 16.40 Mn
Sep 30, 2020 18.64 Mn
Jun 30, 2020 18.88 Mn
Mar 31, 2020 21.16 Mn
Dec 31, 2019 22.07 Mn
Sep 30, 2019 11.19 Mn
Jun 30, 2019 11.62 Mn
Mar 31, 2019 11.34 Mn
Dec 31, 2018 9.53 Mn
Sep 30, 2018 5.01 Mn
Jun 30, 2018 5.86 Mn
Mar 31, 2018 6.17 Mn
Dec 31, 2017 5.66 Mn
Sep 30, 2017 6.13 Mn
Jun 30, 2017 6.78 Mn